Evotec Investor Day Presentation Deck

evotec Development costs per asset Cost per asset increased ~2/3rd since 2010, in US$ bn 1,981 PAGE 9 1,188 2010 2019 2010 Peak sales per drug Average sales more than halved since 2010, in US$ bn 816 Industry dynamics suggest need for disruptive approach in R&D R&D megatrends > 367 2019 +67% -55% R&D budgets continue to grow in US$ bn 160 IRR 2015 Commercial returns decrease 10% - 200 2015 2020 - 2% 2020 Source: Visiongain - Drug Discovery Outsourcing Market Forecast 2015-2025 and Evotec's estimates; -80% +25% "The IRR turn around challenge" needs new business models

View entire presentation